Biomarkers in Studies of Cancer Prevention

PILOT STUDIES
- Small test population at increased risk

EXPANDED STUDIES
- Larger survey population at increased risk

PUBLIC HEALTH INTERVENTION
- General population

MARKERS ANALYZED
- Measure preneoplastic biomarkers of:
  a) abnormal cell proliferation
  b) abnormal cell differentiation
  c) preneoplastic gene expression

- Measure preneoplastic biomarkers and benign neoplasms:
  (a-c) plus dysplastic and benign tumors

- Measure incidence of cancer

Small test population at increased risk
Larger survey population at increased risk
General population
Measure preneoplastic biomarkers of:
  a) abnormal cell proliferation
  b) abnormal cell differentiation
  c) preneoplastic gene expression
Measure preneoplastic biomarkers and benign neoplasms:
  (a-c) plus dysplastic and benign tumors
Measure incidence of cancer

Small test population at increased risk
Larger survey population at increased risk
General population
Measure preneoplastic biomarkers of:
  a) abnormal cell proliferation
  b) abnormal cell differentiation
  c) preneoplastic gene expression
Measure preneoplastic biomarkers and benign neoplasms:
  (a-c) plus dysplastic and benign tumors
Measure incidence of cancer


We are indebted to Dr. M. Lipkin for information and photographs. *Top left:* Henry Quastler, M.D., 1908–1963, radiobiologist, Biology Department, Brookhaven National Laboratory, Upton, NY; *top right:* Charles Philippe Leblond, M.D., Ph.D., Professor and Chairman, Emeritus, Department of Anatomy, McGill University, Montreal, Quebec, Canada; *bottom left:* Martin Lipkin, M.D., Member and Attending Physician, Memorial Sloan Kettering Cancer Center, New York, NY, and Professor of Medicine, Cornell University Medical College; *bottom right:* Eleanor Deschner, Ph.D., Associate Laboratory Member, Memorial Sloan-Kettering Cancer Center, New York, NY.